Chandelier
Senior Member (Voting Rights)
Evolution and description of long-term COVID-19 pulmonary sequelae: study design
Abstract
Initial post SARS-CoV-2 (COVID-19) infection studies have demonstrated the presence of short and medium-term functional, radiological and clinical pulmonary sequelae.
However, the prevalence and long-term progression remain unknown.
Of all the possible sequelae, pulmonary fibrosis is likely to be the main complication; therefore, the detection of biomarkers of profibrotic activity could help to identify the most susceptible patients.
The aim of this protocol is to describe the presence and progression of long-term (5-year) post-COVID-19 pulmonary functional, radiological and clinical sequelae.
This study design, called LONG_COVID FIBROTIC (2025), is an observational, prospective, multicenter and extension protocol based on a previous study cohort (COVID FIBROTIC, 2020–2021).
All patients will be scheduled for clinical and functional assessment.
Patients who have unresolved radiological COVID-19 findings assessed during the previous study (COVID FIBROTIC), will undergo a computed tomography (CT) scan.
In addition, in those centers with biobank availability, serum samples will be taken for the analysis of fibrosis biomarkers (metalloproteinase [MMP] 1, MMP7, periostin and KL-6).
This is a methodological description of a protocol study design.
The results are likely to provide a detailed description of the COVID-19 long-term pulmonary sequelae, as well as the possible biological factors involved in their development.
Web | DOI | Scientific Reports | Open Access
Tarrasó Castillo, Julia; Carbonell-Asins, Juan A.; Fernandez-Fabrellas, Estella; Safont Muñoz, Belén; Sancho-Chust, José N.; Cabanes-López, Luis; Amat Humaran, Beatriz; Molina Peinado, Virginia; Herrera Lara, Susana; Ros Lucas, José A.; Fernández-Sánchez, María Carmen; Atarés López, Sara; López - Ramírez, Cecilia; Andreu Rodríguez, Ada L.; Signes-Costa, Jaime
Abstract
Initial post SARS-CoV-2 (COVID-19) infection studies have demonstrated the presence of short and medium-term functional, radiological and clinical pulmonary sequelae.
However, the prevalence and long-term progression remain unknown.
Of all the possible sequelae, pulmonary fibrosis is likely to be the main complication; therefore, the detection of biomarkers of profibrotic activity could help to identify the most susceptible patients.
The aim of this protocol is to describe the presence and progression of long-term (5-year) post-COVID-19 pulmonary functional, radiological and clinical sequelae.
This study design, called LONG_COVID FIBROTIC (2025), is an observational, prospective, multicenter and extension protocol based on a previous study cohort (COVID FIBROTIC, 2020–2021).
All patients will be scheduled for clinical and functional assessment.
Patients who have unresolved radiological COVID-19 findings assessed during the previous study (COVID FIBROTIC), will undergo a computed tomography (CT) scan.
In addition, in those centers with biobank availability, serum samples will be taken for the analysis of fibrosis biomarkers (metalloproteinase [MMP] 1, MMP7, periostin and KL-6).
This is a methodological description of a protocol study design.
The results are likely to provide a detailed description of the COVID-19 long-term pulmonary sequelae, as well as the possible biological factors involved in their development.
Web | DOI | Scientific Reports | Open Access